News Archive

A group of scientists and their supporters are set to march Sunday in Boston’s Copley Square in an event they’ve dubbed “a rally to stand up for science” in the Trump years.

Inside a large nearby convention center, meanwhile, the annual meeting of the American Association for the Advancement of Science (AAAS), the United States’ largest general scientific society, has featured speeches and panel sessions further underscoring the sense that under President Trump, scientists could face wide-ranging political conflicts and challenges, and will have to decide how to meet them.

The products that make cities “smart” will be developed, tested and perhaps scaled in our backyard.

A partnership of the Herndon-based Center for Innovative Technology, D.C.-based Smart City Works and 22 CityLink, the master developer of the Gramercy District smart city planned for Ashburn, is accepting applications for its initial cohort of companies in Smart City Works @ Herndon.

OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures Capital (“3E”).

The new capital will be used primarily to develop a novel clinical stage asset targeting the CD24-Siglec pathway that regulates host inflammatory response to tissue injuries, which has broad implications in the pathogenesis of autoimmune diseases, cancer and graft-versus-host disease (GvHD). OncoImmune will continue clinical testing of its lead clinical product, CD24Fc, in a Phase II trial for the prevention of acute GvHD following myeloablative allogeneic hematopoietic stem cell transplant. CD24Fc has received orphan drug designation for GvHD in both the US and Europe. The funding will also support development of other immuno-oncology (IO) assets with a focus on solid tumor targeting monoclonal antibodies, cancer vaccines, and immunotherapy-related adverse events.

Host:  UM BioPark & Wexford + Technology

Location:  UM BioPark Life Sciences Conference Center 801 W. Baltimore Street Baltimore  Maryland  21201

Time:  5:00pm to 6:30pm

Please join the BioPark’s Monthly Networking Event along with Colleagues from UMBC. Mingle with UM Venture program managers, BioPark tenants, and UMB faculty and staff.

A record number of biotechnology, life sciences and other tech-related companies with a presence in New Jersey stand to benefit from private investments spurred in part by tax credits approved by state officials last year — a sign the Garden State continues to serve as the nation’s medicine chest.

The New Jersey Economic Development Authority announced Tuesday it has approved 251 applications from “angel investors” who are eligible for state income-tax credits to help offset the more than $96 million in private funding they funneled to Garden State tech firms during 2016 — the highest annual total since the program launched three years ago.

What’s the best way to build a startup? Bootstrap it, raise little or no VC funding, and (ideally) sell it for hundreds of millions—or billions—of dollars, according to two venture capitalists.

That’s what they did at least. Andrew Farquharson, now the managing director of InCube Ventures in San Jose, CA, was the chief operating officer of Almeda, CA-based Operon Technologies when it sold to European nucleic acid company Qiagen in an all-stock deal worth around $110 million in 2000. Farquharson and his co-founders tried, but failed, to raise venture funding and instead were able to bootstrap.

Gaithersburg-based NexImmune, a biotech developing immunotherapy treatments for cancer, has been acquired by a consortium of big-name biotech veterans and investors.

Welcome to the fifth edition of the U.S. Chamber International IP Index, “The Roots of Innovation.” This year’s index recognizes the indispensable role of intellectual property (IP), in facilitating innovative and creative activity on a socially transformative scale.

Each economy in the Index presents a unique IP profile. As this Index has grown from 11 economies in its first edition to 45 in the current publication, it has become exceedingly clear that just as elections matter, so do IP policy choices. These choices are not simply a matter of East versus West, developed versus less-developed, or rich versus poor. Rather, the Index represents a broad spectrum of sovereign policy choices. Those choices have important consequences for each economy’s innovative and creative success, and for the collective welfare of all the world’s citizens.

The Big Idea CONNECTpreneur Forum is a Community of over 5000 CEOs, Entrepreneurs, VCs and angels, CXOs and other business leaders in the Mid-Atlantic Region.

Each quarterly CONNECTpreneur Forum mashes up 400+ top founders, investors and business leaders for a morning breakfast event featuring awesome networking, newsmaking speakers, and a showcase of 7-8 exciting early stage companies.

This UNIQUE EVENT is like NONE OTHER in our region, due to the high quality of our attendees and participants, as well as our programming and unprecedented networking.

Most of the attendees are INVITATION ONLY, and we strictly limit service provider participation in order to maximize the experience for our Attendees and Sponsors.

Illumina Accelerator, the genomics-based company creation engine focused on building early stage genomics startups welcomes three new companies to its fifth funding cycle. Since its inception in 2014, Illumina Accelerator has helped startups validate and create next-generation sequencing applications and bring those solutions to market. To date, Illumina Accelerator has invested in 13 startups working to advance breakthrough applications in genomics.